WAIKOLOA, Hawaii — In this Healio Video Perspective from Retina 2026, Ehsan Rahimy, MD, discusses the potential of IL-6 inhibition for the treatment of exudative retinal diseases.
Rahimy said that even with the success of anti-VEGF therapies, many patients with age-related macular degeneration and diabetic macular edema are incomplete or suboptimal responders.
{{VIDEO}}
“That begs the question that other potential pathways may be involved in these disease processes,” he said. “IL-6 is a very important and potent inflammatory marker, which potentiates the activities of VEGF leading to vascular